XARELTO®: Stroke risk reduction in patients with nonvalvular atrial fibrillation (NVAF)
PROVEN ONCE-DAILY,*
24-HOUR STROKE RISK REDUCTION1,2
PROVEN ONCE-DAILY,*
24-HOUR STROKE RISK REDUCTION1,2
*Taken with evening meal.
Demonstrated clinical outcomes in an obesity subgroup population and consistent real-world evidence in patients who have NVAF and morbid obesity3,4
◇For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.
NVAF = nonvalvular atrial fibrillation; VTE = venous thromboembolism.